Q2 EPS Estimates for Pharming Group Reduced by HC Wainwright

Pharming Group (NASDAQ:PHAR) – Equities research analysts at HC Wainwright dropped their Q2 2025 earnings estimates for Pharming Group in a report issued on Thursday, May 8th. HC Wainwright analyst J. Pantginis now anticipates that the company will post earnings of ($0.20) per share for the quarter, down from their previous estimate of ($0.14). HC Wainwright has a “Buy” rating and a $37.00 price objective on the stock. The consensus estimate for Pharming Group’s current full-year earnings is ($0.20) per share. HC Wainwright also issued estimates for Pharming Group’s Q3 2025 earnings at ($0.30) EPS, Q4 2025 earnings at ($0.30) EPS, FY2025 earnings at ($0.90) EPS, FY2026 earnings at $0.10 EPS and FY2027 earnings at $0.60 EPS.

Separately, Oppenheimer lifted their price objective on shares of Pharming Group from $30.00 to $39.00 and gave the company an “outperform” rating in a report on Friday, March 14th.

Pharming Group Stock Up 3.0%

Shares of NASDAQ PHAR opened at $10.00 on Monday. The stock has a market capitalization of $680.31 million, a P/E ratio of -38.46 and a beta of -0.08. The company has a 50-day moving average price of $8.55 and a 200-day moving average price of $8.73. Pharming Group has a 1 year low of $6.65 and a 1 year high of $11.07. The company has a debt-to-equity ratio of 0.41, a current ratio of 3.53 and a quick ratio of 2.76.

Pharming Group (NASDAQ:PHAR) last posted its quarterly earnings results on Thursday, May 8th. The company reported ($0.22) earnings per share for the quarter, beating the consensus estimate of ($0.25) by $0.03. Pharming Group had a negative net margin of 6.09% and a negative return on equity of 7.65%. The firm had revenue of $79.09 million during the quarter, compared to the consensus estimate of $67.74 million.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Pharming Group stock. Silverberg Bernstein Capital Management LLC increased its stake in Pharming Group (NASDAQ:PHAR) by 16.8% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 47,997 shares of the company’s stock after purchasing an additional 6,887 shares during the quarter. Silverberg Bernstein Capital Management LLC owned approximately 0.07% of Pharming Group worth $483,000 at the end of the most recent quarter. Institutional investors and hedge funds own 0.03% of the company’s stock.

About Pharming Group

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.